She has over 25 years’ experience in the global pharmaceutical industry in large pharmaceutical companies, small biotechnology companies, private equity ventures and specialist service provider organisations.
Linda will be an excellent addition to the One Nucleus Board. She has deep understanding of the needs and interests of the SME life science and healthcare community. As the CEO of Immodulon, Linda is passionate about supporting smaller companies within the sector ecosystem. We hope and expect her experience and expertise to help shape our future as we move towards 2020. One Nucleus has worked closely with Linda in recent years in various capacities.
Commenting on her appointment Linda said: “Having worked closely with One Nucleus I am very excited about working with the team to support their future objectives. These are challenging times for life sciences and healthcare companies and One Nucleus is extremely well placed to support the sector. I am delighted to have been asked to join the Board and look forward to bringing my experience to the table, to support the team and assist One Nucleus members.”
Jon Green, Chair of One Nucleus commented: “Linda is a great addition to the team. She has a deep understanding of the needs of One Nucleus members, and this coupled with her current interests, particularly as CEO of a growing biotech company make her an ideal Director for One Nucleus”.
About Linda
Linda is the CEO of Immodulon Therapeutics. Linda has over 25 years in the global pharmaceutical industry in large pharmaceutical companies, small biotechnology companies, private equity ventures and specialist service provider organisations.
Linda worked for 18 years at AstraZeneca, where she held a variety of roles, including project director for Iressa to first registrations in Oncology, Accolate to NDA in asthma, and culminating in being Head of Strategy and Portfolio for the Oncology and Infection Therapy Area Management Team (TAMT).
She was also SVP Portfolio and Project Integration (PPI) at Merck KGaA, based in Darmstadt, leading the portfolio steering committees for Oncology, Cardiovascular and CNS development programmes as well as managing a department of commercial and development personnel.
Latterly Linda became a Senior Partner at TranScrip, a specialist service provider to the pharma and biotech industry, where she leads oncology services and directly supports clients working in oncology. Immodulon is currently her major commitment. Linda has a first degree and PhD from Cambridge UK, and held a NATO post-doctoral Fellowship tenured at the University of California, San Francisco.